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From small molecule generics to biosimilars: Technological upgrading and patterns of 
distinctive learning processes in the Indian pharmaceutical industry.  
 
 
Abstract 
Technology upgrading is a key element of industrialisation and catch-up in developing 
countries. It is understood that a successful technology upgrading is linked to a coupling of 
global knowledge flows with local technology effort. However, the changing nature of 
technology and industries are challenging existing processes involved in the technology 
upgrading and creating new patterns of capability development. This raises the questions 
about factors and processes involved in technology upgrading in firms from developing 
countries. In this context, this paper explores the movement of Indian pharmaceutical firms 
from ‘small molecule generics’ towards targeting a new set of opportunities presented by the 
emergent biosimilar segment in the global generics market. Some leading Indian firms have 
adopted this technological upgrading route by making a gradual transition towards the 
development of biosimilar capabilities and using four case studies; this paper reveals 
internationalisations in the form of overseas acquisitions and collaborations with MNCs formed 
the key basis of technology upgrading strategy for the Indian firms. This paper further shows 
the hiring of biotech scientists working in advanced countries increasing R&D investment and 
reorganisation of R&D contributed to managerial upgrading and played a significant role in 
creating firms’ ability to absorb external knowledge.    
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Introduction 
Technological upgrading is identified as one of the key element of industrialisation in the 
developing countries, and significant attention is paid to the role of ‘technology transfer 
through trade’ and ‘Foreign Direct Investment (FDI)’ as major drivers of technological 
upgrading (Ernst, 2008; Fu et al., 2011; Giroud et al., 2012). In recent years, there has been 
increasing focus on indigenous learning processes and internationalisation in acquisition and 
mastering of technologies that are new to those countries, if not to the world (Amann and 
Cantwell, 2012). The changing nature of technology and industries are affecting the factors 
and processes that are involved in the building of firm-level technological capabilities in the 
developing countries. This raises questions whether firms from developing countries can rely 
on indigenous learning processes to catch up with industrialised countries and whether 
external sources of knowledge such as internationalisation are major drivers of technological 
upgrading for developing country firms. Indian pharmaceutical industry is a good example for 
investigating this question.    
 
Over the last three decades, the Indian pharmaceutical industry has emerged as the 
‘pharmacy of the world' and that growth story has been well documented (Lanjouw and 
Cockburn, 2001; Horner; 2014). The Indian industry employed ‘reverse engineering' to copy 
or manufacture drugs using known processes at a cheaper cost. This ‘imitation strategy' 
contributed to the development of basic technological capabilities in the Indian pharmaceutical 
firms. The signing of the TRIPS (Trade-Related Aspects of Intellectual Property Rights) 
agreement in 1995 restricted the use of reverse engineering and changed the rules of the 
game for Indian pharmaceutical firms. This forced Indian firms to search for a new technology 
strategy and much of the scholarship in the most recent decade has focused on analysing 
technology strategies of Indian firms to this disruptive regulatory change (Athreye et al., 2009). 
As an initial response to the TRIPS-compliant patent regime, leading Indian firms adopted a 
strategy of exploiting process R&D capabilities by targeting small molecule (chemical-based 
drugs) generics markets in advanced countries. This imitation strategy built on existing 
capabilities and involved activities such as identifying needs in the market, locate knowledge 
that would meet the market needs, developing new and original production processes to 
manufacture drugs, and accessing markets in advanced countries. This exploitative process 
R&D strategy emerged as an initial response and became a dominant, widely duplicated 
strategy amongst leading firms in the post-1995 era (Kale and Wield, 2008). This contributed 
to the development of advanced technological capabilities for manufacturing of small 
molecules in the Indian pharmaceutical industry. 
 
However, two decades after the signing of the TRIPS agreement evidence suggests that 
Indian firms are facing significant regulatory and market challenges to technology strategies 
and capabilities focused on small molecule generic markets, thereby threatening their long-
term survival and growth. In this context, some Indian firms have adopted technological 
upgrading route by targeting biosimilar market segment as a new source of growth. Biosimilars 
represent a change in the landscape and a significant market opportunity for the Indian 
pharmaceutical sector. Biosimilars are what might be called generic versions of biologics - a 
therapeutic drug category comprising large complex molecules. Unlike small molecule drugs, 
the challenge of producing similar biological medicine stems not only from R&D but also from 
manufacturing and regulatory requirements. The biological medicines are produced in the 
living systems, and the unique manufacturing process brings in microheterogeneity and 
complexity. Due to these challenges, it is highly difficult to produce an identical copy of the 
nature and production of biological medicines. Thus, these biosimilars are not generics but 
‘similar' to original or reference product regarding safety, efficacy and quality. Manufacturing 
of biosimilars requires different production platforms and expertise in clinical trials 
management. Thus, technology strategies of Indian firms in biosimilar segment require 
significant adaptations and upgrades in such a way that they involve not only activities like 
benchmarking but also notable learning through substantial investment in R&D, production 
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and regulatory capabilities. Further, the complexity of biological drugs and evolving regulatory 
requirements have created a need for new sets of resources, knowledge and capabilities. This 
transition towards biosimilar development provides informative case studies to investigate 
factors and learning processes associated with the technological upgrading and examine their 
link with the development of world-frontier innovative capabilities.   
 
This paper builds on over the last two decades of research on the evolution of technological 
capabilities in the Indian pharmaceutical industry. Using the case study research 
methodology, we selected four Indian pharmaceutical firms to focus our investigation.  Primary 
data was collected through interviews with R&D scientists and key managers from the four 
Indian firms by using a semi-structured questionnaire. Data was triangulated with the help of 
secondary data sources and interviews with industry experts and analysed using a theoretical 
framework based on metrics derived from technological upgrading literature (Radošević and 
Yoruk, 2015). The research demonstrates that Indian firms experimented with technology 
strategy and invested in the development of organisational capabilities to make a gradual 
transition towards acquiring biosimilar capabilities. It does highlights internationalisations in 
the form of overseas acquisitions and collaborations with MNCs formed the key basis of 
technology up-gradation strategy for the Indian firms. This paper further shows the distinctive 
patterns of learning processes and key features of technological, regulatory and market 
strategies involved in technological upgrading by the Indian firms.   
 
This paper is structured as follows: Section 2 briefly reviews the literature focused on the 
technology upgrading of capabilities in developing countries. Section 3 explains the salient 
features of the Indian pharmaceutical industry and highlights challenges to small molecule 
generics market strategy. Section 4 tracks the technological challenges associated with 
opportunities of the biosimilar sector. Section 5 details the data collection methods and the 
four Indian pharmaceutical firm case studies that are used to investigate learning processes 
associated with technology upgrading from small molecule generics to biosimilars. Section 6 
discusses the findings of the research and section 7 concludes with an examination of the 
implications and lessons for policy. 
 
2.0 Theoretical framework: Technological upgrading in developing countries 
Technological upgrading in developing countries is an issue that has been widely discussed 
in the last 20 years by different theoretical research traditions and often discussed in the 
international context. Reviewing this literature, Amann and Cantwell (2012:357) suggest that 
the technological upgrading and economic catch-up literature have ‘tended to disregard the 
firm level and focus on certain macro or industry level environment of economies that are 
beneficial to closing the gap with mature industrialised economies’. Building on that the focus 
of this research is the processes and strategies involved in the technological upgrading in the 
Indian pharmaceutical firms. 
 
Technology transfer, FDI and technology upgrading  
The role of foreign direct investment and technology transfer in technology upgrading has 
been a critical area of research. Fu at al., (2011) suggests that technology transfer through 
the movement of goods, capital, people and international research collaboration may spur a 
learning process and technological upgrading at the local level. In this research, the role of 
multinational enterprises and FDI has received significant attention as key routes for 
technology upgrading in the developing countries (Pietrobelli and Saliola, 2008). FDI as a 
source of technological and managerial knowledge and financial resources has been viewed 
as a conduit for the transfer of advanced technology to developing countries (Lall, 2003). 
However, it is also argued that despite the possible benefits of technology transfer and FDI 
spillover, there may also be significant adverse effects on technological upgrading in domestic 
firms for a variety of reasons (Fu et al., 2011). For example, FDI may negatively affect the 
competitiveness of domestic firms and potentially crowd them out of the market (Hu and 
Jefferson, 2002), and foreign subsidiaries may remain as enclaves in a developing country 
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with a lack of effective linkages to the local economy. Significantly the private interests of the 
MNCs may not coincide with the social interests of developing countries (Lall and Urata, 2003).  
   
Technological upgrading taking place in the Global Value Chains (GVC) has emerged as a 
key area of focus in studies of technology capability development (Hobday, 1995; Gereffi, 
1998). This literature suggests that international knowledge and innovation exchange and 
collaboration has a significant impact on the innovation and technology upgrading of those 
firms that successfully integrate into the GVC. Ernst (2008) points out that in developing 
countries exploiting this potential source of knowledge and learning is especially important 
given that new frontier innovation is rarely created in developing countries and the bulk of 
knowledge and technology needs to be imported. For firms in developing countries, integration 
into GVCs does not only represent a new market for their products, but it also plays a growing 
and crucial role in accessing knowledge and enhancing learning and innovation. However, Fu 
et al., (2011:13) argue that the literature has not yet clearly settled how innovation systems 
and GVCs interact, and how this interaction is likely to affect enterprise learning.  
 
Thus, the central role of technology transfer, FDI and GVCs in technological upgrading and 
driving industrial and economic growth is well established in development and catch-up 
studies, however, Amann and Cantwell (2012) suggests that firm-level technological capability 
building should be the key focus of technological upgrading as it reflects a continual change 
and transformation both the actors and their environment. 
 
Firm-level technological upgrading in the developing countries 
Technological upgrading at the firm level has been the critical area of focus for innovation 
study scholars focused on the development of technological capabilities in the developing 
countries (Bell and Pavitt, 1993, Lall, 1992; Dutrenit, 2000; Figueiredo, 2006; Amann and 
Cantwell, 2013).  Bell and Pavitt, (1993) define technological capabilities as “the stock of 
resources needed to generate and manage technical change, including skills, knowledge and 
experience and institutional structures and linkages”. This definition suggests that 
technological capabilities refer to both; a technical knowledge component which enables firms 
to generate innovations, and an organisation component which enables firms to manage the 
implementation of their in-house innovations and their linkages with external sources of 
knowledge. Different technologies differ greatly in their learning requirements, entailing 
different costs, risks, duration and linkages. This definition further suggests a different set of 
capabilities that need to be acquired, those that are concerned with the organisation, 
coordination and managerial aspects of technological capabilities. These latter capabilities 
often are much more difficult to develop than engineering know-how and include capabilities 
to access complementary assets, absorptive capabilities, and innovation capabilities. All these 
capabilities are required to adopt, adapt, and modify technologies developed elsewhere, to 
introduce modifications and incremental innovations, and eventually to generate new products 
and processes (Malerba and Nelson, 2012). This insight infers that interactions between 
technical capabilities and organisations capabilities are a key issue in the technological 
upgrading in developing country firms. This literature further suggests that technology 
upgrading is not an automatic process; some latecomer firms succeed, and others fail in 
catching up with the technological frontier (Dosi, 1988; Lall, 1992; Hobday, 1995; Bell and 
Pavitt, 1993). However, Figueiredo (2006:6) argues that “more effort is needed to expand the 
focus of analysis to not only within boundaries of the latecomer firm but also the links between 
capability building within the firm and other external factors such as innovation systems and 
macroeconomic policies”.   
 
Over the years few studies have tried to explain the building of firm-level innovative 
technological capabilities in the late industrialising countries by focusing on intra-firm 
strategies (Dutrenit 2006; Athreye et al., 2009) and taking external factors into account (Kim 
and Nelson, 2000).  These firm-level studies in the catch-up literature tend to focus on the 
significance of imitation in the development of innovative capabilities (Kim and Nelson, 2000). 
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Mainly focussing on creative imitation, Kim and Nelson (2000:5) argue that “most innovations 
do not involve breakthrough inventions but are deeply rooted in existing ideas”. Elaborating 
on this further, Malerba and Nelson (2012) point out that “catching up does not mean cloning”. 
They suggest that the outcome of an imitation effort reflects modifications required to fit 
practice to local contexts. Due to this, the development process involves innovation in the 
Schumpeterian sense: ‘as a break from traditional ways of doing things’. Using the conceptual 
framework focused on the paths and width of technology upgrading (fig 1), Radosevic and 
Yoruk (2015) suggest that these firm-level studies have shown paths of upgrading of firms in 
developing countries through a variety of interrelated, sometimes similar and sometimes 
unique taxonomies. They conceptualise technology upgrading as a three-dimensional process 
and argue that technology upgrading is multidimensional processes and consists of three 
major dimensions: technology, structural change and interaction with the global economy. 
 
Further, sectors change over time following life cycles in a coevolutionary process along with 
various actors, knowledge and institutions. In some cases, evolution is triggered by changes 
in demand, users and applications, and that can alter the context in which firms operate 
(Christensen and Rosenbloom, 1996). This results in changes in technological and learning 
regimes and patterns of innovation (Malerba and Nelson, 2012) and can lead to a change in 
the knowledge base of innovative activities, requiring new types of competencies. This 
dynamic and evolutionary view implies that the boundaries of sectoral systems regarding 
knowledge, actors, and institutions may evolve, with new types of actors entering and new 
vertical and horizontal linkages and interdependencies formed among industries and 
technologies (Malerba and Nelson, 2012). Amann and Cantwell (2012) argue that this trend 
towards a greater interdependence and international integration in the processes of firm-level 
capability building has an impact on the national specific ecosystem, giving rise to the 
importance of internationalisation and global knowledge flows in studies of firm-level 
technology upgrading. They point towards the ‘rising globalisation of the technological 
knowledge bases, the internationalisation of epistemic and professional communities of 
practice and related science as well as the increased international interconnectedness of 
business relationships as a major influence on the firm level technological upgrading’ (Amann 
and Cantwell, 2012:355). Building on that Radosevic and Yoruk (2015:11) argues that a 
successful technology upgrading is never entirely autonomous process, but it is always linked 
to the inflow of foreign knowledge skills, which are coupled with domestic technology effort. 
Reviewing this technology upgrading literature, Fu et al., (2011) raises key unanswered 
questions about nature of interactions and relationship between indigenous innovation and 
acquisition of foreign technology in an increasingly globalised world This suggests a need for 
unpacking the nature of interactions, processes and strategies involved in leveraging domestic 
innovation effort with global knowledge flows. Further, Bell and Figueiredo (2013) argue that 
the study of the technological capability development in latecomer firms operating in the 
intensive technological sector has been limited and under-researched. This paper builds on 
and adds to the research focused on firm-level factors and processes involved in technology 
upgrading by exploring internationalisation strategies and learning processes involved in the 
development of biosimilar capability by the Indian pharmaceutical firms.  
 
3.0 The Indian pharmaceutical industry 
The Indian pharmaceutical industry ranks 3rd regarding volume and 14th in terms of value. It 
was valued at $12 billion in 2013 (Panchal et al. 2014). It comprises 250 large units (which 
includes the public sector, domestic firms and foreign subsidiaries), and 8000 small-scale 
units. The large units contribute almost 70% to total national pharmaceutical activity and 
therefore dominate the Indian pharmaceutical sector. The Indian pharmaceutical industry has 
come a long way. From importing bulk drugs, it has moved into exporting formulations to the 
highly-regulated markets of the developed world. It represents one of the most successful 
cases of self–reliant development in post-independence India.   
 
The dominance of small molecule generics business model 
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The growth of the Indian pharmaceutical industry was slow until the patent act of 1970 and 
government investment which closely followed. The 1970 Patent Act allowed patents only for 
production processes and not products, triggering an era of reverse engineering. The Indian 
pharmaceutical firms focused on adapting technology to firm and country specificity, and 
efforts in these directions fostered the development of a knowledge base. These firms used 
reverse engineering or duplicative imitation as the primary mechanism for knowledge 
acquisition and built basic process R&D capabilities in the manufacturing of small molecule 
generics. After the liberalisation of the pharmaceutical market in the mid-1990s, some Indian 
pharmaceutical firms moved toward the highly regulated generic markets in advanced 
countries. Indian pharmaceutical firms initially exported formulation products to least 
developed and developing countries, but after 1990 they started exporting formulation 
products to generics markets in advanced countries. The technology strategy of ‘incremental 
imitation' involving the manufacture of products by developing non-infringement processes 
which could be converted into a patent creating value for firms emerged as a principle 
response of the Indian firms. Indian firms started developing processes which contained some 
patentable novel elements. This allowed Indian pharmaceutical firms to develop the regulatory 
capability required to access global markets, build organisational structures to manage original 
research, and gain entry to the generic markets of advanced countries. However, emerging 
R&D, market and regulatory challenges in the small molecule generics strategy and 
opportunities in biosimilar market has spurred Indian firms to invest in technological upgrading 
strategy focused on biosimilar as a distinctive alternative source of long-term growth 
 
3.1 Challenges to the small molecule generics business model and need for 
technological upgrading  
The shrinking market share in generic markets due to increased competition and regulatory 
hurdles in advanced country markets created uncertainty about potential sources of long-term 
growth for the leading Indian firms. 
 
Market challenges: Saturation of the market for ‘small’ molecule generics in advanced 
countries 
Indian firms’ business models generally rely strongly on small molecule generics markets in 
advanced countries for revenue and growth. However, the saturation of these markets, in part 
linked to changes in regulation, has significantly reduced the value of these markets for Indian 
firms. Until 2003, many innovative Indian firms generated profit by aiming for first to file status 
in the US generics market, which provided 180 days market exclusivity to generics 
manufacturers. In 2003 however, this provision was diluted allowing for more than one 
generics manufacturer to enjoy the 180-day exclusivity, provided they file their Abbreviated 
New Drug Application (ANDA) on the same day. This dented profit margins significantly. In 
addition, the entry of large pharmaceutical firms into international generics markets has led to 
increased competition, further eroding the profit margins of Indian manufacturers.  
 
Regulatory challenges: Problems with US FDA 
The Indian pharmaceutical industry has the largest number of USFDA (Food and Drug 
Administration) approved manufacturing plants outside the US, and in 2013 accounted for 
39% of all approvals for generic drugs (Balakrishnan, 2014). The strong presence of Indian 
firms in the US market brought about intense scrutiny which resulted in more than 30 import 
alerts received by Indian firms since 2009. The FDA has identified some Indian 
pharmaceutical manufacturers who have had problems with data integrity and Good 
Manufacturing Practices (GMP) at their respective facilities. This data is intended to ensure 
that products meet pre-established specifications for purity, potency, stability and sterility 
(Gaffney, 2015). Since 2013, the FDA has banned around 30 Indian plants for various 
violations (Gaffney, 2015; FDA website, 2015). In 2014, the FDA issued import alerts against 
ten plants, including units of two leading Indian firms; Sun Pharmaceuticals and Cadila 
Pharmaceuticals.   
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3.2 Biosimilar: Opportunities and challenges 
A biologic or biological drug is a large complex molecule that has been sourced from a living 
cell, for example, insulin. Traditionally biologicals have been developed to address the most 
challenging illnesses such as cancer, autoimmune diseases, diabetes, growth hormone 
deficiency and inflammation. Biosimilars are similar in terms of quality, safety and efficacy to 
an already licensed reference biological product – it is an interchangeable generic equivalent. 
Unlike small molecule generics, biosimilars are produced in living organisms, heterogeneity, 
with ‘some allowable’ structural variations are fully expected when compared to innovator 
product (Rader, 2014). The chemically synthesised small molecule is expected to be 
equivalent (not just similar) to the reference product.  
 
Opportunities  
The growth in the biosimilar market is driven by several factors such as original biologics 
coming off patent, pressure on governments all over the world to reduce healthcare costs, and 
the development of regulatory guidance in key markets around the world. With clinical testing 
not including large Phase III type efficacy and safety studies, biosimilar requires less 
investment and time for their development and thus, provides cheaper alternative and more 
competition for reference products previously lacking generics type competition (Rader, 2014). 
 
The global market size of biologics was estimated at US$169 billion in 2012 (IMS, 2013). 
Various patents for top-selling biologics are due to expire between 2012 and 2019, creating a 
biosimilar market worth of $100 bn by 2020 (Wechsler, 2011). Biosimilars are poised to 
acquire a significant share of the generics pharmaceutical market. Singh (2015) suggests that 
globally, revenues from biosimilars have risen from $1.1 million in 2007 to $86.9 million in 
2014. There are already 21 approved biosimilars in Europe, and many of the 150 biosimilars 
in development will also be introduced into the European market. It is expected that biosimilars 
will account for 4% to 10% of the global generic market total by 2020.  
 
Governments in different countries and regions are establishing new regulatory guidelines to 
facilitate the entry of affordable biosimilars. Major developed regions such as the EU, US, 
Japan, and Canada and many of the largest emerging markets such as China, Brazil, South 
Africa, and India have established biosimilar pathways or produced regulatory guidelines 
specifically for complex biosimilars. Moreover, in 2010 the WHO offered guidance on 
biosimilar approval standards for regulatory agencies to use as a basis for local requirements.  
There is a certain convergence around regulatory requirements and the emergence of a 
significant new market opportunity. By establishing a common development platform for most 
markets, the Indian firms minimise the duplication of effort across pre-clinical and clinical 
development, accelerate development, and reduce investment costs.  
 
3.2.2 Challenges in the development of biosimilar capability 
Switching to biosimilars is not an easy, minimum risk strategy. Biosimilars are too complex to 
manufacture in the same way as simple small molecule drugs (e.g. aspirin) and require 
considerable financial and organisational investment in developing regulatory, technical and 
scientific capabilities. Table 1 lists some key differences between small molecule generics and 
biosimilars.  
 
Table 1 Difference between small molecule and biosimilar product development 
(Jonker-Exler, 2015) 
 
Key issues  Small molecule  Biosimilar  
Example Acetylsalicylic acid (Aspirin) (180 
Da) 
Monoclonal antibody 
(~150,000Da) 
Entity Chemical Protein 
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Structure Small, simple, well characterised Large, complex, heterogeneous 
Stability Stable Unstable 
Manufacturing 
process 
Predictable and precise method, 
identical copies in batches 
Living cell-based complex 
technology; batch to batch 
variation, sensitive to storage and 
handling 
Knowledgebase Chemistry based requiring 
strong process R&D skills  
Biology-based process R&D and 
manufacturing capabilities 
Mode of 
administration 
Usually amenable to ingestion Usually, requires injection or 
infusion 
Regulatory  Uniform requirement of 
bioequivalence data for product 
approval in advance and 
developing country markets  
Challenges of forming uniform 
regulation in advance markets but 
requires clinical trials data 
Immunogenicity Mostly non-immunogenic immunogenic 
 
 
Elaborating on the distinction between the biosimilar and small molecule generic, McKinon 
and Lu (2009) point out ‘complexity' as a critical difference. Conventional drugs can be 
characterised entirely based on their chemical structures, whereas biological drugs tend to be 
recombinant proteins with structural complexity and high molecular weight. The complexity of 
biological drugs emanates from the elaborate manufacturing and regulatory processes 
involved in their production. Due to the complexity of the manufacturing process, the possibility 
for variance is very high, and a slight variability in process or input can lead to slightly different 
large complex molecules, which in turn can have significant effects on safety, quality and 
efficacy. As a result, biosimilars are considerably more expensive to manufacture than small 
molecule generics. For example, the production cost of small molecule generics manufactured 
using classical chemical synthesis can be less than US$5 per gram, while biological produced 
in living cells incur costs of US$ 100-1000 per gram (Sommerfeld and Strube, 2005). It is 
imperative for manufacturers to find a production process that would keep the cost affordable 
to patients for doses at higher than 5 mg/kg body weight and week. Thus, technical 
competencies are required for upstream verification of similarity or comparability with an 
innovator product and downstream pharmacovigilance data generation.  
 
The challenge of different knowledge base: Process R&D and Manufacturing 
capabilities  
Accessing small molecule generics markets in advanced countries involved creating non-
infringing processes or invalidating an existing patent. The knowledge base for this builds on 
organic and synthetic chemistry skills (accumulated through reverse engineering). Some 
Indian firms have used this base to add a patentable, innovative element that provides value 
through leveraging process R&D capabilities. In the case of biosimilars, these firms need 
expertise to reverse-engineer biologics and develop stable, therapeutically active cell lines. 
They also need to develop manufacturing processes to meet specifications and to invest in 
new infrastructures for controlling living cells, purification and producing biologic products 
consistently at commercial scale (Lee et al., 2011). In the manufacturing of biological drugs, 
product quality is defined by the process (e.g. equipment, the sequence of unit operations, 
operation parameters) because no complete analysis of these complex molecules is possible 
(Sommerfeld and Strube, 2005). As a result, the production process is fixed after the first 
clinical lot production in a pilot plant leaving no scope for modifications or optimisations parallel 
to production whereas, in small molecule productions, it is possible to perform process 
optimisation in parallel to production. This difference in the manufacturing process demands 
an advanced level of biological process R&D and production capabilities for the development 
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of biosimilar. Joe Thomas, CEO of Stellis Biopharma points out limitations of production 
technology currently used by Indian manufacturers, 
 
“The earlier model of Indian generic companies with strong domestic franchise 
investing in capacities to meet international requirements is not practical in a 
biopharma setting. Unlike generics, biosimilar uptake is relatively low in India because 
of their high cost, and biomanufacturing capacity creation is much more resource 
intensive than in small molecule.” 
(Stanton, 2017) 
 
In this regard, the main constraint for Indian firms is the lack of knowledge of biology pertinent 
to biosimilars and absence of expertise with regards to quality, safety and efficacy (Interview, 
senior scientist, Serum Institute of India, 2014). 
 
The challenge of different knowledge base: Regulatory capabilities   
In the case of small molecule generics markets, Indian firms have to conduct bioequivalence 
or bioavailability studies to establish similarity of the therapeutic product and novelty of 
production process to get approval from regulatory authorities to sell in the market. However, 
in the case of biosimilars, Indian firms are facing severe challenges in satisfying the regulatory 
requirements for biosimilars, which are not only different from that, which applies to generics 
and biologicals but also differ from country to country and involves the collection of extensive 
clinical data requiring clinical trials over a more extended period.  
 
To enable cost-effective global development, Indian firms will need to consolidate their efforts 
to harmonize development requirements, particularly their choice of global reference products 
and how they define them. The complexity of the manufacturing process requires multiple 
points of comparison to reference product. Thus, the creation of the creation of structural 
analytic goalposts or reference points for developing highly similar products will call for trade-
offs and design expertise combined with an understanding of the likely clinical implications 
(Daalgard et al., 2012). Further, as biosimilar progresses through comparability stage-gates, 
both pre-clinical and clinical studies are required to make a full assessment of the similarity of 
a candidate biosimilar to its reference product. For instance, difficulties arise in using in vivo 
pharmacokinetic/pharmacodynamic (PK/PD) and toxicological models because complex 
biosimilars demonstrate species-specific pharmacodynamics profiles that limit the 
extrapolation of data from one species to another. Indeed, there is no established in vivo 
pharmacology model other than non-human primates, and as a result, extensive in vitro 
assessments are needed (Radar, 2014; Daalgard et al., 2012). Thus, the understanding the 
possibility and consequences of even small variation requires knowledge in new fields of 
biology. The head of biosimilars at a leading Indian firm further illustrates this with the example 
of immunogenicity. In the case of small molecules, drugs rarely elicit immune responses, but 
large molecules such as biologicals can trigger immune responses of different consequences 
(Interview, 2014). In the case of biosimilar candidates, there must be equivalent 
immunogenicity compared to a reference biologic. Also, establishing systems for phase IV, 
post-market adverse event reporting and generation of pharmacovigilance data involves long-
term financial investment and superior organisation capability. 
 
 Financial and infrastructural resources  
The regulatory frameworks, rigorous clinical trials and extensive clinical data required for 
biosimilars create financial and technological capability challenges for Indian firms. The 
average cost of clinical development for biosimilar ranges from $40 million to $300 million, 
and development takes up to 5 years; comparatively, development costs $2 to $5 million for 
a generic drug and takes 2 to 3 years (Grabowaski et al., 2014). G.V. Prasad, vice chairman 
and CEO of Dr Reddy Labs (DRL) explains; 
 
 10 
 "It is a big game. It will cost at least $20 million to take a biosimilar drug to the 
European market. It takes only a small fraction of that amount for a conventional 
generics pharma product." (Suresh, 2008) 
 
Referring to financial challenges, a senior pharmaceutical scientist based at Utrecht University 
in the Netherlands argues: 
 
"[US and European] markets will be dominated by ‘Big Pharma'. It takes between 50 
and 100 million euros to develop a biosimilar that meets the regulations in Europe, the 
US and Japan…. that is in addition to post-marketing costs and pharmacovigilance 
demands. I do not see how a small company, especially from India and China, even if 
they have the technical skills and money to develop a high-quality biosimilar could be 
able to compete with Teva, Sandoz or Hospira" (Interview, Jayaraman, 2010) 
 
In this context, for Indian industry acquisition of biosimilar capability will require investments 
in technology upgrading by the reorganisation of R&D, building a new manufacturing and 
regulatory capabilities.    
 
5.0 Research Methodology 
This paper investigates the firm level learning processes and interactions with the external 
environment involved in the technology upgrading in the Indian pharmaceutical industry by 
focusing on the case studies of four Indian pharmaceutical firms (Table 2). 
 
The principal reasons for focussing on these firms are twofold. One, the four firms selected 
for the study are among the top 20 Indian pharmaceutical firms. Further, there is a robust 
correlation between size and R&D intensity in the Indian pharmaceutical sector (Pradhan, 
2007). Therefore, any investment in the biosimilar market is likely to emerge only from the top 
firms. Second, the firms selected for study operate in both; small molecule generic markets as 
well as biosimilar markets. Further, these firms are at different stages of developing biosimilar 
product portfolios and thus provide ideal cases to track challenges involved in technological 
upgrading. Firms such as Biocon and DRL are early entrants in biosimilar and small molecule 
generic market while Lupin/Cipla is a late entrant. 
 
Table 2 Firms under study (Annual Reports, 2016) 
 
Firms Nature of 
firm 
Turnover 
2016-17 
Rs ₹ million  
(approx. US 
$ million) 
Biosimilar Products  Supply of 
Biosimilar in 
the 
overseas 
market 
Biocon   Biotech  
40787 
(636.89) 
Human insulin, Insulin 
Glargine, Erythropoietin, 
Filgrastim, Streptokinase, 
Itolizumab, Trastuzumab 
27 countries 
Cipla 
 
Pharma 146300 
(2284.47) 
Etanercept India 
DRL  
 
Pharma-
biotech 
148000 
(2311.00) 
Filgrastim, Rituximab, 
pegfilgrastim, darbepoetin 
alpha 
12 countries  
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Lupin Pharma 174943 
(2731.73) 
Filgrastim, Peg-Filgrastim,  India 
 
This study builds on the over last two decades of the research on the evolution of technological 
capabilities in the Indian pharmaceutical industry. In 2016-17 intense data collection was 
carried out to gather primary data on biosimilar capability development in the Indian 
pharmaceutical industry. The data collection primarily focused on the external linkages and 
distinctive learning processes involved in the development of biosimilar capabilities. Primary 
data for the case studies was collected through interviews with R&D presidents, senior 
scientists and heads of biotech R&D in the four firms. In parallel, interviews with a key member 
of the Indian pharmaceuticals industry association and with a senior sector specialist journalist 
were conducted. In total 20 interviews lasting 45-60 mins were conducted. Interviews were 
recorded and transcribed. This data was triangulated by using information from various 
secondary sources such as annual reports, analysts’ presentations and articles in the 
business press.  
 
The literature review on technological upgrading at the firm level in emerging countries 
provides major categories for investigation. It highlights the need to expand focus on factors 
within boundaries of the firm and also explore links between capability building within the firm 
and other external factors such as innovation systems and macro-economic policies 
(Figueiredo, 2006). Based on the that a semi-structured questionnaire was used with 
questions focused on the response of Indian firms to the factors and processes involved in 
technological upgrading from small molecule to biosimilars. Interviews focused on firm 
strategy, challenges and organisational learning activities involved in the acquisition of new 
knowledge required for biosimilar capability development. It also covered questions regarding 
the relevance of existing pharmaceutical R&D and manufacturing in the development of 
biosimilar capabilities and differences with small molecule generic markets.     
 
We employed an analytical framework based on the ‘dimensions and paths’ framework 
proposed by Radosevic and Yoruk (2015) (Fig 1). Dimension 1 consists of the intensity of 
technology upgrading as depicted by different types of innovation activities and dimension two 
is about the spread or width of technology such as diversity of technological knowledge, the 
firm’s structure. Dimension 3 depict knowledge flows into the economy through different forms. 
This framework is modified and employed to analyse data presented in this paper.   
 
The analysis of the empirical evidence was carried out by using various analytical techniques 
such as pattern matching (Yin, 1994) and by the building of analytical tables (Miles and 
Huberman, 1984). Building on the analytical framework a strategy of pattern coding is used to 
identify the processes and strategies involved in technological upgrading within and across 
firms (Eisenhardt, 1989). The theoretical framework provided broad categories for the 
classification of the data, and various pattern codes are classified under those broad 
categories. The key categories included internal organisational changes, motives of 
internationalisation and collaborations and the role of path dependency in shaping new 
capabilities. These patterns were supplemented by secondary data which were collected from 
industry journals, industry association publications and annual reports of firms. 
 
5.0 Firms under study 
This section presents the case studies of technological upgrading in the four Indian 
pharmaceutical firms based on the data collected from primary and secondary sources. 
 
5.1 Dr Reddys Laboratories (DRL) 
Dr Anji Reddy founded DRL in 1984 with the aim of creating an innovative Indian 
pharmaceutical company. DRL started as a bulk drug company and then gradually moved into 
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the formulations business. In 1986, it started operations on branded formulations and within a 
year launched Norilet, DRL's first recognised brand in India. In 1989, DRL's early successes 
were with R&D in non-biologics, notably Omeprazole in 1989 and Fluoxetine in 2001. This 
success was followed by the launch of Ibuprofen tablets in the United States under its brand 
name. In the following decade, DRL emerged as a global generics player with innovative 
process capabilities and stable marketing network in the USA and other advanced countries. 
 
Processes involved in technological upgrading: Biosimilar capability development  
DRL set up biotechnology R&D in 1999 as a separate business unit and within two years 
launched its first biosimilar product, Filgrastim. In 2003, this effort received a boost with the 
hiring of Dr Cartikeya Reddy from Genentech Corporation as head of the Biological division. 
With extensive experience and knowledge in biotechnology R&D, Dr Cartikeya Reddy helped 
DRL to accelerate the development of its biosimilar business and in 10 years succeeded in 
launching three more biosimilars; Darbepoetin, Alfa Pegfilgrastim and Rituximab. In 2007, 
DRL had a breakthrough in biosimilars when it became the first company in the world to launch 
Rituximab biosimilar, referencing Roche's original $6 billion cancer drug, Rituxan. By 2010, 
DRL was operating with three dedicated biological manufacturing facilities and a team of more 
than 300 scientists and engineers. At this stage, DRL adopted a strategy of commercialising 
its biosimilars in emerging markets as a step towards gaining approval in the US and Europe. 
This strategy allowed DRL two advantages. First, it helped the company to gather significant 
real-world experience and clinical data on the performance of its products and, second, it 
provided DRL with an opportunity to generate revenue that could be utilised for developing 
assets for approval in advanced country markets. Following on from that strategy, in 2010, 
DRL began selling its Rituximab in emerging markets at a 30-50% discount compared to the 
innovator brand. 
 
In 2012, DRL started planning to enter the US and European markets. As part of that strategy, 
DRL entered an alliance with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, 
in June 2012. Merck KGaA is a global pharmaceutical company with proven expertise in 
developing, manufacturing, and commercialising biopharmaceuticals. The partnership was to 
co-develop and globally commercialise a portfolio of biosimilar compounds in oncology, 
primarily focused on monoclonal antibodies (mAbs). The alliance allowed DRL to mitigate the 
risks involved in developing a biosimilar — the cost is pegged at $100-200 million, with 70% 
going towards clinical development. By 2013 DRL had started applying for approvals from 
regulators from advanced countries. In 2013, the company filed a US investigational new drug 
(IND) application for its proposed Rituximab biosimilar and Pegfilgrastim and received 
permission to proceed with the Phase-I trials in 2014. At present, DRL is involved in planning, 
designing and executing studies under these INDs. In 2016 DRL in-licensed three biological 
drugs from Amgen to sell in the Indian domestic market.   
 
In 2017 DRL installed India's first single-use manufacturing platform to expand the biologics 
production capacity at its facility in Hyderabad. This platform allows multi-product 
manufacturing and improves productivity by increasing the number of batches that are 
manufactured. This marks a significant step for the DRL and Indian industry regarding 
upgrading of production capabilities for development of biosimilars.  
 
5.2 Biocon 
Biocon, established in 1978, is a fully integrated biotechnology company focused on biologics, 
custom and clinical research. In the mid-1990s, Biocon decided to focus on 
biopharmaceuticals rather than enzymes and set up an in-house biotech research 
programme. After the 2001 patent expiration on Lovastatin, one of the earliest cholesterol 
blockers, Biocon obtained permission from the US Food & Drug Administration (FDA) to sell 
the generic in the US. In 2001 Biocon became the first Indian company to sell Lovastatin in 
the US. 
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To generate an alternate source of revenue and develop regulatory capabilities, Biocon 
established Syngene in 1994, a contract research company, and Cyngene, a clinical research 
organisation, in 2000. These ventures helped Biocon to develop complementary capabilities 
in clinical R&D, generate a steady stream of revenue and establish collaborative linkages with 
overseas pharma companies. 
 
Processes involved in technological upgrading: Biosimilar capability development  
The big breakthrough for the company came with the development of a human insulin product 
in 2003. Biocon became the first company in the world to manufacture insulin using a Pichia 
pastoris yeast expression system. Spurred by this success in 2006, Biocon initiated its 
biosimilar strategy by establishing India’s largest multi-product biologicals R&D facility at 
Biocon Park in Bangalore. Biocon biosimilar strategy has two critical elements which involve 
a) exploiting the success of insulin by expanding it in overseas market and parallel, b) 
developing technological capabilities for monoclonal antibodies (mAbs) and proteins used in 
treatment for diabetes and oncology.  
 
Biocon has created significant capabilities for manufacturing of insulin through the indigenous 
learning process and became the second Indian company to launch human insulin in the 
Indian domestic market causing an almost 40 per cent drop in the price of insulin products. In 
2005, Biocon started expanding in overseas marked by supplying human insulin to countries 
in Africa and the Middle East and now has approvals in over 60 emerging markets for its rh-
Insulin and in over 20 emerging markets for its Insulin Glargine. In 2008, for €30 million, Biocon 
acquired a majority stake in the German pharmaceutical company AxiCorp GmbH (70%) to 
market and distribute its insulin biosimilar and analogues in the German market but dissolved 
this partnership in 2011 while retaining rights to market products in Germany.  
 
In 2010 Biocon entered a landmark $350mn deal with Pfizer to globally commercialise several 
of Biocon's insulin products - Recombinant Human Insulin, Glargine, and Lispro. This deal 
signalled the coming together of Pfizer's strong marketing and commercialisation capabilities, 
especially in the highly regulated developed markets of the world, and Biocon's expertise in 
biotech R&D. Pfizer changed its strategy and pulled out of the deal in 2012.  
 
In 2010 Biocon started setting up Asia's largest integrated insulins manufacturing facility in 
Malaysia at an investment of over $ 250mn, and currently, employs a team of over 400 people 
at this state-of-the-art facility in Malaysia. This is Biocon's first overseas biopharma 
manufacturing and research facility and has received the cGMP certification from the National 
Pharmaceutical Control Bureau (NPCB), Malaysia. Biocon also emerged as the first Indian 
company to have made inroads in Japan, one of the world's most stringent developed markets, 
with its Insulin Glargine. Further, Biocon is developing an insulin analogues portfolio for other 
developed markets like the US and Europe. In 2017 Biocon has agreed with Mexico's 
Laboratorios PiSA to develop and commercialise its rh-Insulin in the US market. 
 
Unlike indigenous effort involved in the development of insulin capabilities, Biocon’s 
development of technological capabilities for complex biosimilars involved internationalisation 
of R&D and overseas collaborations with MNCs. In 2006 Biocon entered a joint venture with 
the Cuban Institute of Monoclonal Antibodies (CIMAB), the commercial branch of the Center 
for Molecular Immunology (CIM) to develop antibodies and cancer therapies and followed that 
with a joint venture with Abraxix Bioscience to develop a biosimilar version of Filgrastim in 
2007. In the same year, Biocon hired Dr Barve from a US biotech firm to lead its clinical 
research organisation and two years later promoted him to head of biotech R&D.   
 
Under the leadership of Dr Barve, Biocon adopted an aggressive strategy of targeting 
emerging as well as advanced country markets and to achieve that, entered a range of 
collaborations and joint ventures. In 2009 Biocon formed a strategic joint venture with Mylan, 
an MNC generics firm, to co-develop four biosimilars and enter the global biosimilar market. 
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Over the years, this collaboration developed a strong portfolio of generic insulin analogues 
and biosimilars including monoclonal antibodies (mAbs) and recombinant proteins, with 
products on track for approvals with different regulatory agencies. During 2017, the Marketing 
Authorization Application (MAA) for a proposed biosimilar Trastuzumab was accepted by the 
European Medicines Agency (EMA) for review. This is the second biosimilar submission 
developed by the partnership that has been accepted for review in Europe. Earlier in 2017, 
Mylan's MAA for the proposed biosimilar Pegfilgrastim was also accepted for review by EMA. 
Further, the results of two pivotal Pegfilgrastim studies were have confirmed the comparability 
of the efficacy, safety and immunogenicity profiles of Pegfilgrastim versus the reference 
product (annual report, 2016). The third biosimilar Transtuzumab is in Phase III clinical trials 
while the global phase III clinical trial for Adalimumab is progressing well across multiple sites. 
The global phase I study for Bevacizumab is approaching completion while the ROW focused 
phase III trial is advancing.  
 
Biocon’s successful growth into a fully integrated biotech company with a strong biosimilar 
portfolio and an extensive presence in international markets was founded on a targeted 
programme of organic growth and investments in biotech R&D.  
 
5.3 Cipla 
Cipla was established in 1935 by Dr A K Hamied with the aim of making India self-sufficient in 
terms of its healthcare needs. Over the last five decades, Cipla has developed extensive 
capabilities in process R&D and has emerged as a global supplier of cheap generic drugs. 
Cipla's international generics strategy was boosted in 2001 with the launch of antiretroviral 
drugs (ARVs) in emerging country markets at comparatively low prices. By 2012 Cipla was 
credited with transforming the global HIV-AIDS treatment landscape, and it had also emerged 
as one of most successful Indian firms with an average annual growth rate of more than 20%. 
 
According to Capron and Mitchell (2012), Cipla’s success in international generics markets 
lies in its business model, building a broad portfolio of products to achieve economies of scale 
in production and creating a network of alliances and licensing agreements with a wide range 
of other organisations with complementary skills and resources. However, the transformation 
of the Indian domestic market due to the strengthening of Indian patent act in 2005 and 
increased competition from global generic manufacturers has created new challenges for 
Cipla's existing business model.  
 
Processes involved in technological upgrading: Biosimilar capability development  
In 2000, these challenges forced Cipla to embrace biosimilars as a key area of future growth. 
However, to achieve success in the biosimilar market, Cipla had to overcome major hurdles 
in the form of R&D and manufacturing capabilities. Cipla had no previous experience of 
biotech R&D or innovative drug discovery R&D, and as a family-owned business, Cipla lacked 
the professional management required to succeed in the emerging biosimilar market. To 
overcome these knowledge gaps Cipla embarked on an ambitious strategy that involved 
acquisitions of biotech firms, entering inward co-licensing deals and hiring senior management 
professionals from competitor MNC firms to create top management teams experienced in 
international markets. 
 
To accelerate biosimilar development, in 2004 Cipla in partnership with Avesthagen (an Indian 
biotech company), created Avesta Biologicals Ltd, a new biotech company. In 2007, Avesta 
Biological acquired Siegfried Biologicals, a biotech company based in Germany, to access 
biological R&D expertise. However, this did not lead to the expected progress on biosimilar 
R&D and in 2009 Cipla decided to dissolve Avesta Biologicals due to lack of progress in the 
development of biosimilars from Avesthagen.    
 
To overcome this failure in 2010 Cipla acquired a 25% stake in MabPharm, an India based 
biotech firm and helped it to set up a state of the art biotechnology manufacturing facility in 
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India. In 2014 Cipla gained full ownership of the manufacturing plant by acquiring the 
remaining 75% share. In parallel to the MabPharm acquisition, Cipla invested $65 million to 
acquire a 40% stake in Bio Mabs, a Shanghai-based biotech aimed at developing ten 
monoclonal antibodies (mAbs) and fusion proteins against rheumatoid arthritis, cancers and 
asthma for marketing in India and China. 
 
To complement these acquisitions, Cipla decided to build a biosimilar product portfolio through 
in-licensing. In 2013, Cipla launched its first biosimilar product, Etanercept, through in-
licensing from China-based Shanghai CP Guojian Pharmaceutical Co, remarkably at a 30% 
reduced price over competitor brands. In 2014, Cipla in-licensed a second biosimilar, 
‘Darbepoetin alfa’, by entering a co-marketing deal with Hetero Drugs, an Indian biotech 
company. Over the years, Cipla has created partnerships in manufacturing, sales and 
marketing with firms all over the world. In 2012, a new management team initiated a strategy 
to convert these partnerships into subsidiaries and joint ventures to bolster complementary 
capabilities. In 2012, Cipla acquired a distribution partner in South Africa, Cipla Medpro South 
Africa, for $512 million and followed that by increasing its stake in a Uganda-based joint 
venture, Quality Chemical Industries Ltd (QCIL) from 14.5% to 51.05% for $15 million.  
 
To advance biosimilar development, Cipla set up of Cipla BioTec, a 100% subsidiary to 
research, development, manufacturing and marketing organisation focused on biosimilar 
products. In 2016, Cipla BioTec invested US$89 mn to establish a biosimilar manufacturing 
facility in South Africa. However, there are concerns about Cipla’s biosimilar strategy as its 
core business differs significantly from the biosimilar and has raised issues of capital allocation 
to fund further expansion.    
 
5.4 Lupin Pharmaceuticals 
Dr D B Gupta started Lupin Pharmaceuticals Ltd in 1968, and over the years Lupin dominated 
the anti-TB market by becoming the largest producer and supplier of anti-TB drugs; 
Ethambutol and Rifampicin all over the world. By 2017 Lupin expanded its dominance over 
small molecule generic business in advanced countries by emerging as 4th in the US by 
prescriptions and sixth largest generic pharmaceutical player in Japan (annual report, 2017). 
 
Like Biocon, in 2011 Lupin established the Lupin Bioresearch Center (LBC) to conduct clinical 
and bioequivalence studies for generic products and branded formulations. These allow Lupin 
to develop complementary capabilities in regulatory R&D and establish collaborative linkages 
with overseas pharma companies. 
 
Processes involved in technological upgrading: Biosimilar capability development 
In 2008 Lupin entered the biosimilar sector by setting up the Lupin Biotechnology Research 
Group to develop biosimilars for India and other emerging countries. In 2010 Lupin hired Dr 
Cyrus Karkaria from a US-based biotech firm as president of Biological R&D to lead its efforts 
in biosimilars.  By 2018 Lupin’s biotech facility acquired a talent pool of close to 300 people, 
consisting of approximately 11 per cent PhDs and 63 per cent post-graduates. Under the 
leadership of Dr Karkaria, Lupin chose a strategy of targeting the products that are difficult to 
develop, have an entry barrier and therefore a larger competitive interest in the long run. 
Another key part of the strategy was to target regulatory approvals in Japan and EU before 
launching products in India as it will reduce expenditure on conducting India specific clinical 
trials. This might delay the product launch in India but it will also company to learn from other’s 
mistakes (Rowchoudhari, 2018) 
 
In 2012 Lupin entered into a licensing agreement with Sydney-based NeuClone for proprietary 
cell-line technology to be developed into biosimilar drugs targeting the oncology segment and 
in May 2015 launched Filgrastim and Peg-Filgrastim in the Indian market. In the same year, 
Lupin entered a strategic distribution agreement with LG Life Sciences of South Korea to 
launch Insulin Glargine, a novel insulin analogue in the Indian market. This allowed Lupin to 
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expand its biosimilar portfolio and opportunity to work with leading South Korean biosimilar 
developer. In 2014 Lupin entered a joint venture with Yoshindo, a Japanese biotech company 
to form YL Biologics (YLB) to conduct clinical development of certain biosimilars including 
regulatory filings and obtaining marketing authorizations in Japan. YLB will be jointly managed 
by both partners and will in-license monoclonal antibodies (mAbs) from Lupin and partner with 
other companies for the Japanese market. Lupin’s etanercept biosimilar was the first product 
to be licensed for clinical development to YLB, and it is currently undergoing phase III clinical 
trials on over 500 patients across Japan, India and Europe.   
 
6.0 Analysis and Discussion  
The case study narratives describe the processes involved in technology upgrading of the 
Indian pharmaceutical firms as they move from small molecule generic business to biosimilar.  
 
Table 3 unpacks the case narratives and presents lists the key patterns of technological 
upgrading and their differences with small molecule generics by breaking down the 
technological capabilities into the sub-categories and matching them with nature and process 
involved in the technological upgrading.  
 
Table 3 Nature and processes involved in technology upgrading 
Capabilities Nature of 
upgrade  
Processes involved in the technology upgrading  
 
Small molecule  biosimilar 
R&D Move from 
chemistry-
based R&D to 
biological R&D 
Built on existing process 
R&D capabilities by 
promoting non-infringe 
process development 
 
Acquisition of new 
knowledge by hiring 
scientists based 
overseas experienced in 
biotech R&D 
 
Links with public research 
institute as key source of 
external knowledge  
In-licensing of technology 
from MNCs or other 
emerging country firms 
Supplier arrangements with 
MNCs and overseas firms  
Co-development 
agreements with MNCs 
and overseas firms 
Technology  Development 
of 
organisational 
capabilities to 
manage a 
distinctive 
portfolio of 
generics 
Assets exploiting 
acquisitions of generic firms 
based in advanced 
countries 
Asset building acquisition 
of biotech firms based in 
advanced countries  
Production  Manufacturing 
of large 
complex 
molecule and 
advanced 
production 
platforms 
Small molecule 
manufacturing platforms 
with GMP certification and 
USFDA authorisation 
Advance single-use 
biological manufacturing 
platforms with GMP 
authorization and 
greenfield investments in 
overseas countries 
Regulatory  Move from 
bioequivalence 
to clinical trials  
Strong in-house capability in 
bioequivalence or 
bioavailability tests  
Outsourcing of clinical 
trials or collaborating with 
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It suggests that internationalisation, collaboration with MNCs and hiring overseas Indian 
biology scientists as sources of external knowledge formed a core technology strategy for 
Indian pharmaceutical firms in their development of biosimilar capabilities (Table 3).  These 
strategies have been elaborated in the following section.  
 
6.1 Technology upgrading strategies  
The Indian firms move towards the small molecule generics R&D represented a natural 
progression for Indian firms; it built on their superior process R&D capabilities and in-depth 
knowledge of organic and synthetic chemistry. However, in the case of biosimilars, Indian 
firms required technological upgrading to carry out certain functions and activities such as 
bioprocess development and cell-line development (interview data). These firms adopted 
combinations of four strategies to fill these technological gaps: 1) Internal investments and 
reorganisation; 2) Import of technology and knowledge; 3) Internationalisation of production, 
distribution and marketing and 4) Collaboration with MNCs.   
 
6.1.1 Internal investments: Setting up biotech dedicated R&D and manufacturing 
plants 
The Indian firm strategies to develop biosimilar capability involved increasing the level of 
biotech R&D investment, building biological R&D facilities and setting up biotech as a separate 
business division. Majority of Indian firms have increased R&D spend over the past five years, 
in absolute as well as the percentage of sales terms. While absolute spend is still less than 
international generics MNCs but few Indian firms spend is higher in terms of R&D intensity 
(percentage of sales) (Table 4). Biocon and Lupin have also set up in-house CROs to develop 
their absorptive capacity in the areas of biosimilar commercialization where they perceive the 
significance of their own capabilities and sense cost advantages—e.g. in clinical trials. Both 
firms have exploited their process development skills to undertake contract research (in 
clinical research trials and process development) for MNCs. 
 
Table 4 R&D intensity in Indian firms 
 
 2013 2014 2015 2016 
Biocon 8.8 6.1 7.5 11.5 
DRL 6.6 11.8 11.5 13.9 
Cipla 4.6 5.6 6.3 7.6 
Lupin 8.4 8.7 11.7 13.5 
 
 
6.1.2 Import of technology and knowledge 
Indian firms have focused on the import of production technology, final products and scientists 
in their effort to develop technological and managerial capabilities required for the 
development of biosimilars. The key focus in biosimilar development is highly complicated 
biological production process. Contrary to the highly predictable chemical production 
processes, the biological production process is more complicated, and that creates managing 
manufacturing process a continuous challenge for the biosimilar developer. In response, some 
MNCs for clinical 
development 
Market 
access  
Move to high-
value markets 
of biosimilars 
Internationalisation focused 
on accessing advanced 
country markets 
Target on the domestic 
market and other 
emerging countries 
Competition with MNCs 
involving patent challenges  
Collaborations and co-
development agreements 
with MNCs and emerging 
country firms  
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Indian firms have transitioned from use of stainless steel to single-use technology.  In 2017, 
DRL imported single-use technology platform from General Electric to employ at their 
manufacturing plant in India. This production platform enables DRL to enhance flexibility and 
efficiency in their manufacturing set-up. Single-use technologies facilitate multi-product 
manufacturing and improve productivity by increasing the number of lots manufactured. 
Highlighting the benefits of the technology, Stelis’ CEO Joe Thomas comments,  
 
"We believe that single-use technologies will dramatically improve quality and 
compliance to regulation by eliminating the possibility of cross-contamination through 
the use of disposable components. Also, high level of process controls through 
automation eliminates manual intervention and enhances traceability of process 
parameters giving greater comfort to regulatory authorities. The higher batch cost on 
account of disposables will be offset by the reduction in batch failures, faster 
changeover between batches, no cleaning validations, lower utility cost and greater 
capacity utilisation. This should certainly attract more global manufacturing into India."    
(Stanton, 2017) 
 
 
Gradually some other Indian firms are moving towards the use of single-use technology for 
manufacturing of biosimilars. For example, in 2017 Stellis Biopharma, a leading Indian firm in 
collaboration with MilliporeSigma, Merck KGaA’s life science division opened a ‘Joint Process 
ScaleUp Lab’ employing the ‘single-use technology’ at its biologics R&D facility in India.  
 
The hiring of overseas scientists, managers and engineers 
In the case of biosimilars, Indian firms lacked an in-house knowledge base. Indian firms are 
trying to acquire specific knowledge (in biosimilar production, development and regulation) by 
hiring Indian scientists working with MNCs and biotech firms in advanced countries. All case 
study firms show evidence of the development of biosimilar R&D capability through the hiring 
of scientists. A head of the business strategy at the Indian firm comments, 
 
“One of the biggest challenges that we have right now is talent scarcity. That remains 
so, but we are unique as we have a presence in India, presence in Basel, presence in 
New Jersey. The company’s global organisations give us access to that kind of talent 
pools. For example, if you look at the senior leadership of this organisation, apart from 
the head of biotech R&D, other four VPs that are leading the product development are 
also from the US. They are based in different regions around the world; our head of 
clinical development is based in the UK, head of the commercialisation is based in 
Basel, and head of manufacturing is based in Singapore. These kinds of global talent 
we access. This trend will continue, and it will pay off in the future because in India 
there is a scarcity of talent.” 
      (author interview, 2016) 
 
Indian firms attract these scientists by offering leadership positions and providing scope to 
develop their biological business (Table 5). These scientists have been instrumental in 
establishing the biotech R&D facility with the goal of developing and producing biosimilars for 
the global market. For example, Dr Cyrus Karkaria set up Lupin’s biotech R&D and built 
scientist teams to work on biosimilar development. A head of biotech R&D from leading Indian 
firm comments, 
 
“The other big thing is that India is growing, but it is not like IT sort of business. In 
pharmaceutical expected, biological skill sets are limited especially at the middle level. 
They have not been exposed to correct ways of doing things, and I would say that 
people are very hungry to learn. However, it is our responsibility to train them so that 
they can acquire the required skills.”  
(author interview, 2016) 
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This managerial upgrading is a significant part of the technology upgrading at the Indian firms 
as it allows firms to internalise external knowledge and build local teams. These scientists also 
contribute significantly to scouting for collaboration and acquisition deals by bringing some 
science intelligence as well as their networks to internationalisation activity of these firms. Dr 
Cyrus Karkaria comments,  
 
“We negotiated with each global authority and are” doing the spade work” looking for 
partners for the US market.”  
         (Rowchoudhury, 2018) 
 
Table 5 Hiring of Indian biotech scientists from overseas 
 
Firm Year Current role  Previous overseas connection 
Biocon 2010 - 
2015 
Dr Abhijit Barve, R&D 
President 
Working with Astellas, a US biotech 
company as a Global  
Development Project Leader 
Biocon  2015 Dr Narendra Chirumule, 
Sr Vice President, Head 
of R&D  
Executive director, Amgen (2007-14) and 
Director, Merck (2000-2007)  
DRL 1999 Dr Cartikeya Reddy, 
Head Biologicals division 
Working with Genetech Inc., as a Group 
Leader in Cell Culture Process Development 
Lupin 2010 Dr Cyrus Karkaria 
President, Biotech 
Division 
Leading a biotech company in the US 
Cipla 
 
2012 
 
Subhanu Saxena, CEO 
 
Head, Global Product Strategy, Novartis 
Pharma AG 
 
 
In some instances, these scientists revived and catalysed the development of biosimilar in 
Indian firms through their networks of scientists in overseas countries, understanding of 
biosimilar business and providing guidance on the collaboration activities. A head of 
manufacturing at the Indian firm comments, 
 
“When I came here there was the limited scale of efforts and largely around the first 
generation of biologic. Mostly I would say the products that were not very industrial in 
their scale. We started there and built on that”.  
 
This is also clearly evident in the example of DRL. Sudrendran (2016) points out that DRL 
struggled with the development of biosimilars in its first attempt. In late 1990 DRL’s biological 
business suffered a significant setback when original patent holder Roche pointed out that 
DRL’s version of filgrastim had a different sequence of amino acids compared to its own and 
that the copy could not claim to be the same drug.  This resulted in the departure of head of 
biotech R&D in 2003 with no leadership of biotech division at DRL. The business was again 
revived in 2004 after Dr Cartikeya Reddy came on board. Dr Cartikeya Reddy was working 
with Genentech as a Group Leader in Cell Culture Process Development. Dr Anji Reddy 
offered him an opportunity to lead DRL biological R&D as an independent integrated business 
unit. Dr Cartikeya Reddy is credited with developing DRL’s biosimilar capabilities and playing 
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an instrumental role in putting the building blocks to the long-term sustainability of biosimilar 
business by entering a partnership with Merck Serono.  
 
 
6.1.3 Internationalisation of production, distribution and marketing 
In the post-1990 era, Indian firms invested to ensure compliance with Good Manufacturing 
Practices (GMP) standards for the manufacture of small molecule generics. This was a key 
requirement for FDA approval and access to generics markets in advanced countries. Indian 
firms also acquired production facilities in advanced countries. Building on these 
complementary capabilities, Indian firms have made greenfield investments in overseas 
countries for manufacturing of biosimilars and supplying to other emerging as well as 
advanced countries. For example, Biocon production facility in Malaysia was commissioned 
in 2010 and was certified by Malaysia’s National Pharmaceutical Regulatory Authority (NPRA) 
in 2015. This facility is dedicated by the Biocon to supply insulin glargine – co-developed with 
Mylan – in Europe. Biocon received the big boost in 2017 with a contract from the Malaysian 
government for supply of its rh-insulin and pen delivery device to local firm CCM 
Pharmaceuticals for distribution to service primary health care clinics and hospitals across 
Malaysia. 
 
The leading Indian firms have established a strong marketing and distribution presence in 
small molecule generic markets all over the world including advanced countries. This has 
created significant complementary capabilities (Teece, 1986) and an in-depth understanding 
of overseas markets, facilitating the entry of Indian firms into international biosimilar markets. 
Similar to the entry into small molecule generics markets, in the case of biosimilars, the Indian 
firms have focused on the emerging country markets and collaborating with local firms to de-
risk their investment. Biocon, DRL and Cipla are also collaborating with overseas firms based 
in emerging country markets to access markets overseas. A head of biologicals from an Indian 
firm suggests, 
 
We basically have a business-to-business model in biosimilar markets; we access 
various regions of the world through commercial partners. For example, to pick up the 
Latin American region we work with the local pharma company to get access to that 
market. We still haven’t built up the strength ourselves in understanding nuances of 
the domestic biosimilar market. For example, going to the Latin American market and 
understanding how the regulators work, understanding how the prescriber players 
behave there, setting up the distribution network, this kind of nuances. Instead of 
investing in those ourselves it is easier for us to find a like-minded partner to take us 
to market quickly and bring us those capabilities right away. 
        (author interview, 2016) 
 
It is quite evident that Indian firms collaborating with other emerging country firms are focused 
on gaining market access in contrast to linkages with MNCs in advanced markets which are 
aimed at capability building. 
 
6.1.4 Collaboration with MNCs and emerging country firms 
The Indian firms chose to collaborate and interact with overseas research institutes and firms 
in advanced countries to fill knowledge gaps and reduce development costs. These firms 
entered different types of collaborations with MNCs. In some cases, these collaborations 
involved co-development of biosimilar while other collaborations involved in-licensing of 
biosimilar and technology transfer (Table 6). 
 
Indian firms’ co-development agreements with MNC leverage their strong development and 
manufacturing capability and MNC’s strength in managing regulatory filings and 
commercialisation. These co-development collaborations are specifically focused on the 
commercialization of monoclonal antibodies as the regulatory pathway for biosimilar mAbs is 
 21 
longer, the physician acceptance is expected to be lower, and competition from innovative 
products is high (Jonker-Exler, 2014). A typical strategy involves Indian firms handling product 
development, manufacturing while MNC takes the lead in late-stage clinical trials and 
commercialization in advanced markets. An R&D head at a leading firm commented,  
 
“Now we are focusing on more global development efforts so we are investing in 
technologies, investing in partnerships that can give us some late-stage capabilities 
and that can help us access markets like the US and Europe”.  
(author interview, 2016) 
   
Table 6 Key R&D collaborations for biosimilars (Annual reports, company website) 
 
Other types of collaboration have involved in-licensing of biosimilars and biological drugs for 
MNCs to market in domestic and other emerging markets. For example, DRL entered into a 
collaboration with Amgen for in-licensing of biosimilars and biological drugs. Some of these 
deals have also involved significant technology transfer along with the in-licensing of the 
biosimilars. Ipca, an Indian firm collaboration with Oncologics, a US-based biological firm 
involves in-licensing of biosimilars but also requires Ipca to create a new R&D facility in 
Mumbai that will be modelled on the Oncobiologics facility.  Furthermore, Oncobiologics, in its 
joint venture, will be offering specialised biologics training at its R&D site in the US for certain 
Ipca scientific staff as the two firms look to build a bio-manufacturing plant in India. 
Oncobiologics VP Business Development, Stephen McAndrew points out,  
 
Year Indian 
firm 
MNC Nature of alliance 
2004 Biocon Vaccinex (USA) Co-develop at least four therapeutic antibody 
products 
2006 Biocon Cuban Institute of 
Molecular Immunology 
(Cuba) 
Development of antibody for treating cancer  
2007 Biocon Abraxis (USA) Out-licensing of Peg-Filgrastim to Abraxis for 
regulatory development and commercialisation 
in the US and Europe   
2009 Biocon Amylin (USA) Co-development of novel peptide hybrid for 
treatment of diabetes.  
2009 Biocon Mylan (USA) Co-development of six Monoclonal Antibodies 
(mAbs) (Trastuzumab, Pegfilgrastim, 
Adalimumab, Bevacizumab, Etanercept and 
Filgrastim) 
2010 Biocon Pfizer (USA) Insulin and analogues (Pfizer: marketing and 
sales)  
2011 Lupin Neuclone (Australia) Access to cell line technology to develop 
biosimilar drugs used in cancer treatment 
2012 DRL Merck Serono 
(Switzerland)  
3 mAbs (joint development) 
2014 Lupin Yoshindo (Japan) Co-development and commercialisation of 
etanercept 
2016 Biocon Lab PiSA (USA)  Co-development and commercialisation of rh-
insulin in the USA 
2017 DRL Amgen (USA) In-licensing of 3 biologicals 
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“The design infrastructure, training and know-how will occur via direct transfer in the 
US initially. Over time the manufacturing will be ‘tech transferred’ to India so that 
biologics manufacturing costs can be minimised, but only after establishing high-
quality expertise (via onsite training) and establishing appropriate quality control 
systems.”  
         (Stanton, 2017) 
These co-development agreements bridge key technological skill, managerial capability gap 
and financial weakness of Indian firms and allow them to target highly competitive advanced 
country markets.  
 
The evidence presents a strong association between internationalisation and technological 
upgrading in the Indian firms. However, it also shows that Indian firms’ internationalisation and 
R&D collaboration strategies in biosimilar differed significantly from small molecule generics 
market. In small molecule generics focus of internationalisation was clearly built to assess 
exploiting behaviour by leveraging process R&D capabilities and low-cost manufacturing. In 
contrast, evidence shows that in biosimilars these firms are entering collaboration and 
embarking on internationalisation process to achieve world-leading process R&D and 
manufacturing capabilities.  
 
6.2 Dimensions and paths of technology upgrading in the Indian pharmaceutical 
industry  
Evidence from case studies suggests the development of biosimilars is shaping the evolution 
of new capabilities and strategies in Indian pharmaceutical firms. Radosevic and Yurik (2015) 
conceptual framework is modified and employed to track the technology intensity, paths and 
width of technology upgrading in the Indian pharmaceutical industry (Fig 1).   
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Fig 1 Dimensions and paths of technology upgrading (author modification of Radosevic and Yoruk., 2015) 
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In this model complexity of the knowledge base, risks and rewards are plotted against different 
levels of technological intensities and capabilities. Based on Bell and Figueiredo (2013) a 
basic level of capability is taken as the ability to make minor adaptations to production and 
assimilate technology into a firm's environment. The intermediate capability is the ability to 
generate incremental technical change in product design, quality and production processes; 
it also includes the ability to search and evaluate external sources of technology. Advanced 
capabilities refer to the ability to catch up with the international technological frontier and 
closing in on leading global incumbents, perhaps with differing directions of innovation. With 
biosimilars, a significant degree of risk is evident in the projected future growth of the market, 
the evolving regulation and the position of emerging country suppliers. 
 
Technology intensity is activated based on the criteria of domestic behind the technology 
frontier towards world frontier technology efforts. In the global generic business, 
manufacturing of active pharmaceutical ingredients, formulations and bulk drug represents the 
basic capability and behind the technology frontier activities while small molecule generics in 
advanced countries and biosimilars can be viewed as world frontier activities. However, the 
complexity of the knowledge base, the need for managerial and organisational capabilities to 
handle more onerous manufacturing, regulatory and marketing demands, and technology 
intensity associated with biosimilars make it a truly world frontier technology and advanced 
capability. It indicates that a technology upgrading process is being followed that will 
eventually allow firms to accumulate capabilities to enable them to produce novel biologics.  
 
Further, Singh (2015) points out that currently, an estimated 150 biosimilars are under 
development, and many of large firms such as Amgen, Boehringer Ingelheim, Merck, Novartis, 
and Pfizer. For example, Pfizer is gearing up for the biosimilar market with its purchase of 
biosimilar manufacturer Hospira, while Amgen has at least nine biosimilars under 
development and yet to launch its first biosimilar in the US market. It suggests that biosimilar 
is an emergent market segment where Indian firms and leading MNCs are at similar stages of 
product development (table 7). In this context, for Indian industry, development of biosimilar 
capabilities represents competing at the technological frontier of global generic business.  
 
Table 7 Competitive landscape and Indian firms’ biosimilar regulatory filings in 
advanced markets   
 
Molecule Biosimilar Development pipeline 
Pre-clinical Phase I Phase II/ filed Approved/marketed 
Peg-
filgrastim 
Pfizer DRL Biocon, Apotex  
Coherus, 
Sandoz, Cinfa 
 
trastuzumab Oncobiologics, 
DRL 
Meiji Seika Biocon, 
Celltrion,  
Samsung, 
Amgen, Pfizer, 
Hanhwa 
 
insulin 
glargine 
  Biocon - EMA, 
Samsung  
Biocon – Japan,  
Eli Lilly – EU, US, JP, 
CAN  
Samsung - EU 
adalimumab Epirus  Biocon, 
Samsung, 
Sandoz, 
Boehringer 
Ingelheim, 
Amgen  
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Coherus, 
Momenta, Pfizer, 
Fresenius, 
Fujifilm-Kirin - 
EMA, 
Oncobiologics 
bevacizumab Celltrion Sandoz, 
Daiichi, 
Oncobiologics, 
Cipla 
Biocon;  
Amgen, 
Boehringer 
Ingelheim, Pfizer, 
Samsung, 
Fujifilm-
Kirin/Astra 
Zeneca, DRL 
 
filgrastim Biocon, Pfizer  Apotex  Sandoz; Teva, 
Apotex, Hospira, 
Fuji  
etanercept Biocon, 
Celltrion 
Hanwha Coherus, Lupin - 
Japan 
Samsung, Sandoz  
rituximab  DRL - FDA  Mylan, Pfizer, 
Teva,  
Sandoz - EU, 
Celltrion – EU,  
Mundipharma - EU 
 
Evidence also highlights the significance of complementary capabilities as small molecule 
generics have created key knowledge bases, understanding of generics business and global 
networks of suppliers and retailers. However, this research also reveals that some pre-existing 
capabilities learned through experience with small molecule generics markets constrained the 
development of biosimilar R&D and regulatory capabilities. All firms under study invested in 
setting up new R&D infrastructure, organisational practices and regulatory capabilities as 
existing infrastructure and practices became secondary, though not completely obsolete in the 
new environment. Studies of other industries suggest that some resources, processes and 
capabilities that served firms well in the past become obsolete where there is a new technology 
and discarding these activities forms important aspect of adding new knowledge (Leonard-
Barton, 1992). Biosimilar capabilities are therefore being developed in parallel with small 
molecule generics. 
 
6.3 Role of government policy and internal markets 
Amann and Cantwell (2012) suggest that in the studies of technological upgrading attention 
must be paid to the regular interaction between firm-level capability building and policy-making 
as a co-evolutionary process, as opposed to a set of separate actions. In case of biosimilars 
development, the Indian pharmaceutical industry proactively worked with the government to 
set up regulatory guidelines for biosimilar approvals in India. They argued for guidelines, 
scientific principles and approaches to be like those of the EMA (European Medical Agency) 
and USFDA. As a result, in 2012 the Department of Biotechnology (DBT) in consultation with 
industry and scientists, devised guidelines for biosimilar products titled ‘Similar Biologics: 
Regulatory Requirements for Marketing Authorisation in India’. These guidelines cover the 
regulatory pathway regarding the manufacturing and quality aspects of biosimilars in India and 
list the pre-approval regulatory requirements for the comparative quality, safety, and efficacy 
as demonstrated by the comparative quality, non-clinical and clinical studies. These strict 
regulations in the domestic market coupled with the technological complexity of developing a 
biosimilar made it harder for Indian firms to produce and market their biosimilars in the 
domestic market. These resulted in only a few Indian firms entering the Indian biosimilar 
market, and these firms had to make significant investments along with greater R&D and 
market effort to succeed in the domestic market. This shows that the challenging domestic 
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market played a key role in the development of significant technological upgrading in the 
Indian pharmaceutical industry. This is important point as it is contrary to the conventional 
thinking in the literature focused on the technological capability building in late-comer firms 
which suggest that the export market is more demanding and more conducive to the 
acquisition of advanced technological capability.  
 
7.0 Conclusion  
Over the last three decades, the Indian pharmaceutical industry has dominated small molecule 
generics market based on skills in chemical synthesis and advanced process R&D 
capabilities. However, saturation and reduction of value in small molecule generic markets in 
advanced countries have forced Indian firms to look at complex biosimilars, creating a need 
for a new knowledge base and an alternative path to the upgrading of technological 
capabilities.  Using the case studies of four Indian pharmaceuticals firms, this paper explores 
the factors and processes involved in the development of biosimilar capabilities in the Indian 
pharmaceutical industry. This paper shows that the technological upgrading process in the 
Indian pharmaceutical industry consists of advanced technological intensity and high 
diversification and complexity of the knowledge.  
 
Employing the ‘dimensions and paths’ conceptual framework developed by Radosevic and 
Yurik (2015), this research examines the movement of Indian pharmaceutical firms from ‘small 
molecule generics towards biosimilar segment in the global generics market. This shows that 
development biosimilar capability represents an up-gradation of Indian firms capabilities 
throughout the production process; starting from an upstream expansion of the knowledge 
base and re-orientation of R&D to a downstream enhancement of regulatory and marketing 
capabilities in emerging and advanced country markets. Thus, this development of biosimilar 
capabilities points towards the movement of the Indian domestic industry from behind 
technology frontier effort towards world frontier technology efforts in the global generics 
industry.   
 
Indian firms’ presence in small molecule generic markets in advanced countries and 
competition with MNCs has created an understanding of regulatory challenges, and that has 
influenced their relationship with overseas firms in the emerging area of biosimilars. Evidence 
presented in this paper reveals a strong role of internationalisation and R&D collaborations 
with MNCs in the development of biosimilar capabilities. It is also evident that Indian firms 
collaborating with other emerging country firms are focused on gaining market access in 
contrast to linkages with MNCs in advanced markets are aimed at leveraging regulatory costs. 
Significantly, Indian firms’ collaborations with MNCs specifically involved the development of 
complex products such as mAbs and proteins but relies on indigenous learning process for 
manufacturing of less complex biosimilars such as insulin. This highlights that the relationship 
between capability building and internationalisation is complex, firm-specific and dependent 
on the institutional environment and prevalent modes of international connectedness.  
 
This paper shows that Indian firms adopted distinctive strategies to develop biosimilar and 
these strategies fall into three broad categories: technology acquisition strategies, accessing 
international markets and managing regulatory requirements essential for biosimilar product 
approvals.  Indian firms hired of biotech scientists working in advanced countries increased 
R&D investment and reorganised R&D to create an absorptive capacity and internalise 
external knowledge. These scientists made a significant contribution by helping to set up the 
biotech R&D facility, development of business models, training the workforce and scouting for 
M&A deals. This finding highlights the processes involved in the coupling of global knowledge 
flows with firm-level innovation efforts.  
 
This research also highlights that developing biosimilars for the domestic market was 
technologically more challenging and also involved greater market effort. This is contrary to 
conventional thinking about technological capability building which has usually suggested the 
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export market is more demanding and more conducive to the acquisition of advanced 
technological capability. The findings from this research have implications for pharmaceutical 
firms based in other emerging and developing countries. 
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